Effect of familial clustering in the genetic screening of 235 French ALS families.


Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
05 2021
Historique:
received: 06 09 2020
revised: 23 11 2020
accepted: 26 11 2020
pubmed: 8 1 2021
medline: 4 1 2022
entrez: 7 1 2021
Statut: ppublish

Résumé

To determine whether the familial clustering of amyotrophic lateral sclerosis (ALS) cases and the phenotype of the disease may help identify the pathogenic genes involved. We conducted a targeted next-generation sequencing analysis on 235 French familial ALS (FALS), unrelated probands to identify mutations in 30 genes linked to the disease. The genealogy, that is, number of cases and generations with ALS, gender, age, site of onset and the duration of the disease were analysed. Regarding the number of generations, 49 pedigrees had only one affected generation, 152 had two affected generations and 34 had at least three affected generations. Among the 149 pedigrees (63.4%) for which a deleterious variant was found, an abnormal G4C2 expansion in Our results suggest that familial clustering, phenotypes and genotypes are interconnected in FALS, and thus it might be possible to target the genetic screening from the familial architecture and the phenotype of ALS cases.

Identifiants

pubmed: 33408239
pii: jnnp-2020-325064
doi: 10.1136/jnnp-2020-325064
doi:

Substances chimiques

C9orf72 Protein 0
DNA-Binding Proteins 0
FUS protein, human 0
RNA-Binding Protein FUS 0
SOD1 protein, human 0
TARDBP protein, human 0
Superoxide Dismutase-1 EC 1.15.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-484

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Philippe Corcia (P)

ALS Centre, Department of Neurology, CHU Tours, Tours, Centre, France corcia@med.univ-tours.fr.
UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.

William Camu (W)

Montpellier 2 University, Montpellier, Languedoc-Roussillon, France.

Celine Brulard (C)

UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.

Sylviane Marouillat (S)

UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.

Philippe Couratier (P)

ALS Center, Departement of neurology, CHU Limoges, Limoges, Limousin, France.
UMR-S 1094 NET, Limoges, France.

Jean-Philippe Camdessanché (JP)

Neurology, Saint-Etienne University Hospital Bellevue Site, Saint-Etienne, Rhône-Alpes, France.

Pascal Cintas (P)

Neurology, CHU Toulouse, Toulouse, Midi-Pyrénées, France.

Annie Verschueren (A)

Centre de référence des maladies neuromusculaires et de la SLA, Marseille Public University Hospital System, Marseille, Provence-Alpes-Côte d'Azu, France.

Marie-Helene Soriani (MH)

CHU Nice, Nice, Provence-Alpes-Côte d'Azu, France.

Claude Desnuelle (C)

Centre de reference des maladies neuromusculaires SLA, Neurosciences department, CHU Nice, Nice, Provence-Alpes-Côte d'Azu, France.

Marie-Céline Fleury (MC)

Neurology, CHU Strasbourg, Strasbourg, Alsace, France.

Nathalie Guy (N)

CHU Clermont-Ferrand, Clermont-Ferrand, France.

Julien Cassereau (J)

Neurology, CHU Angers, Angers, Pays de la Loire, France.

Fausto Viader (F)

U1077, INSERM, Paris, Caen, France.

Sophie Pittion-Vouyovitch (S)

Neurology, Hopital Central, Nancy, France.

Veronique Danel (V)

Medical Pharmacology, Lille University Hospital Center, Lille, Hauts-de-France, France.

Ivan Kolev (I)

Hospital Centre Saint Brieuc, Saint Brieuc, Bretagne, France.

Gwendal Le Masson (G)

Neurology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, Aquitaine, France.

Stephane Beltran (S)

ALS Center, Francois-Rabelais University, Tours, Centre-Val de Loire, France.

Francois Salachas (F)

ALS Center, Neurology, Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France.

Emilien Bernard (E)

University Hospital Centre Lyon, Lyon, Auvergne-Rhône-Alpes, France.

Pierre-François Pradat (PF)

Fédération de Neurologie, Centre Référent SLA, Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France.
CNRS, INSERM, Laboratoire d'Imagerie Biomédicale (LIB), Université Pierre et Marie Curie Faculté de Médecine, Paris, Île-de-France, France.

Hélène Blasco (H)

Biochemistry and Molecular Biology Department, Université Francois-Rabelais de Tours, Tours, Centre-Val de Loire, France.
Neurogenetics and Neurometabolomics, Imagerie et cerveau, Tours, France.

Débora Lanznaster (D)

UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.

Rudolph Hergesheimer (R)

UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.

Frederic Laumonnier (F)

UMR 1253 Imaging and Brain, Tours, Centre-Val de Loire, France.

Christian R Andres (CR)

Biochemistry and Molecular Biology Department, Université Francois-Rabelais de Tours, Tours, Centre-Val de Loire, France.

Vincent Meininger (V)

Neurogenetics and Neurometabolomics, Imagerie et cerveau, Tours, France.

Patrick Vourc'h (P)

Biochemistry and Molecular Biology Department, Université Francois-Rabelais de Tours, Tours, Centre-Val de Loire, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH